NCT04649554 is a NA clinical trial of Exablate treatment in Neuropathic Pain, sponsored by InSightec.

Who is sponsoring NCT04649554?

NCT04649554 is sponsored by InSightec.

What drugs are being tested in NCT04649554?

Interventions in NCT04649554: Exablate treatment.

What condition does NCT04649554 study?

NCT04649554 studies Neuropathic Pain.

Is NCT04649554 still recruiting?

NCT04649554 is currently terminated. Last updated 20 March 2026.

Last reviewed 2026-03-20 · How we verify

NCT04649554

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of MRgFUS Exablate Treatment Following the Neuropathic Pain

Terminated NA Last updated 20 March 2026

What this trial tests

NA trial testing Exablate treatment in Neuropathic Pain in 2 participants. Terminated before completion.

Timeline

8 October 2020

Primary endpoint
31 December 2021

3 August 2023

Quick facts

Lead sponsor	InSightec
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	8 October 2020
Primary completion	31 December 2021
Estimated completion	3 August 2023
Sites	1 location across Italy

Drugs / interventions tested

Exablate treatment

Conditions studied

Neuropathic Pain — all drugs for Neuropathic Pain →

Sponsor

InSightec — full company profile →

Who can join

30 and older, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to capture the change in pain intensity, physical/emotional function, and pain impact for patients diagnosed with neuropathic pain who undergo an Exablate treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Magnetic Resonance-guided Focused Ultrasound thalamotomy for refractory neuropathic pain: a systematic review and critical appraisal of current knowledge.
Taranta V, Saporito G, Ornello R, Splendiani A, et al · · 2023 · cited 7× · PMID 37363184 · DOI 10.1177/17562864231180729

Verify or expand the search:

Other trials of Exablate treatment

Trials testing the same drug.

NCT05802511 — Study of Exablate Model 4000 Type 1.0/1.1 Following the Treatment of Neuropathic Pain · NA · completed

Other recruiting trials for Neuropathic Pain

Currently open trials in the same condition.

NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting

Other InSightec trials

Trials by the same sponsor.

NCT04667715 — Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma · NA · withdrawn
NCT05539196 — A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advance · recruiting
NCT05089786 — Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) · NA · unknown
NCT05565443 — MR-guided Focused Ultrasound Plus GCase · NA · recruiting
NCT05317858 — Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04649554 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InSightec
Last refreshed: 20 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04649554.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing